Leerink Partnrs Issues Optimistic Estimate for AUPH Earnings

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP - Leerink Partnrs increased their Q1 2025 earnings per share estimates for Aurinia Pharmaceuticals in a research note issued to investors on Thursday, November 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $0.10 for the quarter, up from their prior forecast of $0.05. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.13 per share.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.08. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.47%. The firm had revenue of $67.77 million for the quarter, compared to the consensus estimate of $59.07 million.

Several other research analysts also recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Finally, StockNews.com raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $10.00.

Aurinia Pharmaceuticals Stock Up 4.1 %

NASDAQ AUPH traded up $0.34 on Monday, hitting $8.66. The stock had a trading volume of 838,534 shares, compared to its average volume of 1,605,829. The business's fifty day moving average price is $7.13 and its 200 day moving average price is $6.13. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -57.26 and a beta of 1.45. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82. Aurinia Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $10.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AUPH. SG Americas Securities LLC grew its holdings in shares of Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company's stock worth $4,015,000 after buying an additional 535,301 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Aurinia Pharmaceuticals in the 3rd quarter valued at about $3,330,000. Stonepine Capital Management LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $1,713,000. AQR Capital Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $1,155,000. Finally, Algert Global LLC increased its holdings in shares of Aurinia Pharmaceuticals by 106.8% in the second quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company's stock valued at $1,107,000 after purchasing an additional 100,104 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.